Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock

Key Points

• Martin Brenner bought 12,336 iBio shares on March 19 at an average price of $2.02, a 67.35% increase in his stake to 30,652 shares (transaction disclosed in an SEC filing).
• iBio shares trade around $2.11 with a market cap of ~$72.7M, a negative P/E (-2.11), a 12-month range of $0.56–$4.86, and the company reported a Q4 EPS loss of ($0.09), missing estimates by $0.01.
• Wall Street coverage is mixed but generally positive overall (average rating "Buy" with a $4.75 consensus price target), and several hedge funds recently initiated small positions; institutions own about 7.9% of the stock.

iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner purchased 12,336 shares of the firm's stock in a transaction on Thursday, March 19th. The stock was bought at an average cost of $2.02 per share, with a total value of $24,918.72. Following the acquisition, the insider owned 30,652 shares of the company's stock, valued at approximately $61,917.04. The trade was a 67.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

iBio Stock Up 0.2%

NASDAQ:IBIO opened at $2.11 on Monday. The firm has a market capitalization of $72.72 million, a P/E ratio of -2.11 and a beta of 1.18. iBio, Inc. has a 12 month low of $0.56 and a 12 month high of $4.86. The business's fifty day moving average is $2.38.

iBio (NASDAQ:IBIO - Get Free Report) last released its earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

Hedge Funds Weigh In On iBio

Several institutional investors and hedge funds have recently modified their holdings of IBIO. PFG Investments LLC purchased a new stake in shares of iBio in the fourth quarter worth about $41,000. XTX Topco Ltd purchased a new position in iBio during the fourth quarter valued at approximately $71,000. Persistent Asset Partners Ltd purchased a new position in iBio during the fourth quarter valued at approximately $76,000. Susquehanna International Group LLP acquired a new position in iBio in the third quarter valued at approximately $37,000. Finally, Cubist Systematic Strategies LLC acquired a new position in iBio in the first quarter valued at approximately $224,000. Institutional investors and hedge funds own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IBIO shares. Lifesci Capital upgraded iBio to a "strong-buy" rating in a research note on Thursday, December 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of iBio in a research report on Monday, December 29th. Wall Street Zen downgraded shares of iBio from a "hold" rating to a "sell" rating in a report on Saturday. JonesTrading began coverage on shares of iBio in a research report on Tuesday, March 3rd. They set a "buy" rating and a $7.00 price target for the company. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $5.00 price objective on shares of iBio in a report on Wednesday, March 18th. Three research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, iBio has an average rating of "Buy" and a consensus price target of $4.75.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.